Invention Grant
- Patent Title: Biocompatible polycaprolactone fumarate formulations
-
Application No.: US14009987Application Date: 2012-04-04
-
Publication No.: US10426867B2Publication Date: 2019-10-01
- Inventor: Michael Brett Runge , Michael J. Yaszemski
- Applicant: Michael Brett Runge , Michael J. Yaszemski
- Applicant Address: US MN Rochester
- Assignee: Mayo Foundation for Medical Education and Research
- Current Assignee: Mayo Foundation for Medical Education and Research
- Current Assignee Address: US MN Rochester
- Agency: Quarles & Brady LLP
- International Application: PCT/US2012/032131 WO 20120404
- International Announcement: WO2012/138732 WO 20121011
- Main IPC: A61L27/18
- IPC: A61L27/18 ; A61L27/26 ; C08G63/08 ; C08G63/60

Abstract:
A polycaprolactone fumarate polymer useful as a matrix material for a biocompatible scaffold for tissue engineering applications is disclosed. The polycaprolactone fumarate polymer can be prepared by reacting caprolactone with an alkane polyol to prepare a polycaprolactone precursor, and then reacting the polycaprolactone precursor with fumaric acid or a salt thereof to prepare the polycaprolactone fumarate polymer. The use of an alkane diol, such as 1,2-propanediol, provides a linear polycaprolactone diol precursor. The use of an alkane triol, such as glycerol, provides a branched polycaprolactone triol precursor. The biocompatible polycaprolactone fumarate formulation releases no diethylene glycol or other undesirable byproducts during degradation.
Public/Granted literature
- US20140099278A1 BIOCOMPATIBLE POLYCAPROLACTONE FUMARATE FORMULATIONS Public/Granted day:2014-04-10
Information query